NCT06430424 Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
| NCT ID | NCT06430424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Relapsed Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-04-05 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-04-05 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Eligibility Criteria
Inclusion Criteria: * age \> 18 years * surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux Exclusion Criteria: * systemic therapy received for non-glioblastoma tumor
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06430424 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Relapsed Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06430424 currently recruiting?
Yes, NCT06430424 is actively recruiting participants. Contact the research team at mathieu.larroquette@chu-bordeaux.fr for enrollment information.
Where is the NCT06430424 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06430424 clinical trial?
NCT06430424 is sponsored by University Hospital, Bordeaux. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.